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inTROduCTiOn
Agomelatine is a melatonergic agonist, which exerts
its effect through Melatonin 1 (MT1) and Melatonin
2 (MT2) receptors, and it is also a selective serotonin
antagonist for 5-HT2C receptors. MT1 receptors are
localized mainly in the suprachiasmatic nuclei (SCN)
and the pars tuberalis whereas MT2 receptors are ex-
pressed in the SCN and retina1,2. Furthermore, agome-
latine increases noradrenaline and dopamine release
specifically in the frontal cortex, while it has no influence
on the extracellular levels of serotonin and it appears
to improve sleep quality, with no reported daytime
drowsiness1,3,4.
Agomelatine (beta-methyl-6-chloromelatonin) is
structurally homologous to melatonin, a neurohormone
involved in the regulation of circadian rhythms, with a
wide-spectrum antioxidant activity5. Melatonin is
thought to be the most effective lipophilic antioxidant
that can easily cross cell membranes6 and the blood–
brain barrier7 (Figure 1).
Agomelatine is absorbed rapidly and satisfactorily
after oral administration but its bioavailability is less
than 5% because of the high first pass metabolism. This
drug is biotransformed mainly by cytochrome P450
1A2 (CYP1A2). It is indicated for Major Depressive
Disorder (MDD) in adults due to its antidepressant
effects. It has also positive effects on sleep architecture
in these patients and it is the first antidepressant drug
which does not block the reuptake of monoamines2,8.
In addition, agomelatine resynchronizes circadian
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ABSTRACT: Introduction: Agomelatine is a prescription drug approved for the treatment of major depressive disorder. It
is a melatonergic agonist and a 5-HT2C antagonist. The cytogenetic behavior of agomelatine has not been studied. The aim
of the present study is the investigation of the in vitro effect of agomelatine on human DNA, by estimating sensitive cytogenetic
indices. Methods: SCEs (Sister Chromatid Exchanges) are considered as one of the most sensitive markers of genotoxicity,
PRI (Proliferation Rate Index) is one of the most reliable markers of cytostatic activity, whereas MI (Mitotic Index) shows
precisely the ability of the cell to proliferate. We have investigated the effect of five agomelatine solutions on SCEs, PRI
and MI of human cultured lymphocytes stained with the Fluorescence plus Giemsa method and estimated with the optical
microscope. Results: Analysis of the results has revealed statistically significant (p<0.001) dose-dependent increase of SCE
frequencies and significant reduction of PRI and MI values on lymphocyte cultures treated with agomelatine. Furthermore,
a correlation was observed between a) the magnitude of the SCE induction and the PRI alterations, b) the magnitude of
the MI alterations and the SCE induction and c) the magnitude of PRI alterations and MI alterations. Conclusions: Agomelatine
at therapeutic doses exhibited dose-dependent cytogenetic activity in vitro. This may provide additional information about
the mechanism of action of the drug. Considering that the use of agomelatine has rapidly increased, further studies in other
cell lines and in vivo experimental settings are needed in order to evaluate its effect on human genetic material.
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rhythms and it has recently been proposed as a treat-
ment for anxiety disorders such as panic disorder (PD)
and social anxiety disorder (SAD) due to its anxiolytic
5-HT2C blokable action. Because of this, agomelatine’s
role has been investigated in pharmacotherapy of ob-
sessive-compulsive disorders (OCDs)3,9,10. Furthermore,
agomelatine seems to be an effective drug for acute
depression in Bipolar Disorder (BD) type II as the cir-
cadian rhythm hypothesis of BD suggests a role for
melatonin in regulating mood11,12.
Finally, agomelatine causes fewer sexual side effects
and discontinuation effects than other antidepressant
medications8,13.
Though literature data about clinical efficacy, safety
and adverse effects of agomelatine are satisfactory, its
behavior at molecular level has not been investigated
at all.
The aim of the present study is to investigate the in
vitro cytogenetic effect of agomelatine on human cul-
tured T-lymphocytes by estimating sensitive indices:
SCEs, PRI and MI. SCEs has been identified as one
of the most sensitive indices among biomarkers of geno-
toxicity, PRI and MI have been used as sensitive indi-
cators for the evaluation of the cytostatic activity of
various environmental hazards or therapeutic agents14.
MATeRiAlS And MeThOdS
In vitro SCe, PRi and Mi assays. Blood given by four
healthy donors 19-21 years old, who were non-smokers,
not receiving any drugs, not consuming considerable
quantities of alcohol and not having suffered any kind
of infection for the last 15 days, was used to be culture
lymphocytes for the SCE, PRI and MI assays. 
Human T-lymphocyte cultures were prepared by
adding in each of six sterile universal tubes containing
5 ml chromosome medium (RPMI-1640, Biochrome,
supplemented with 20% fetal calf serum, 0,63% L-g-
lutamine, 0,63% penicillin/streptomycin and 2% phy-
tohaemagglutinin) at the beginning of the culture life,
the following:
• 11-12 drops of human peripheral heparinized whole
blood
• 0.1ml of 5-bromodeoxyuridine (BrdU) water solution
(500 μg/ml),
in addition, in experimental tubes:
• 0,1 ml agomelatine solutions (A=2.5μg/ml,
B=5μg/ml, C=10μg/ml, D=15μg/ml, E=20μg/ml
final concentrations per corresponding culture)
and
in the control tube:
• 0.1 ml of agomelatine solvent: double distilled water:
ethanol, 9:1.
The agomelatine concentrations B and C were equi -
valent to the most common used therapeutic dosages
per os (25-50 mg/day). The cultures were incubated at
37o C for 72 hours in the dark to minimize photolysis
of 5-BrdU. Colchicine (0.3μg/ml water solution) was
added 2h before the collection of the cultures. The cells
were then collected by centrifugation and exposed to
0.075M KCl for 10 minutes. The hypotonic solution
spreads the chromosomes and hemolyses the red blood
cells. The pellet was fixed three times with methanol:
acetic acid (3:1). Drops of concentrated suspension of
cells were placed on microslides that allow to air dry.
For SCEs, PRI and MI analysis, the slides were stained
by a modification of the fluorescence plus Giemsa pro-
cedure to obtain harlequin chromosomes15.
Statistical Analysis. For SCE estimation, 30 suitably
spread second division cells from each culture were
blindly scored. For PRI calculation 100 cells in the first,
second, third and higher divisions from each culture
were blindly scored. PRI=M1+2M2+3M3+…/100,
where M1, M2 and M3+… are the percent values of
cells in the first, second, third and higher divisions, re-
spectively. For MI analysis, all cell divisions present in
an optical field of 1000 nuclei were scored. MI=number
of cells in mitosis/total number of nuclei (1000). For
the statistical evaluation of the experimental data, Stu -
dent’s t-test was performed to determine whether any
SCE values differed significantly from the controls and
Figure 1. 
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the χ2-test was used for PRI and MI comparisons. Sim-
ple linear correlation between SCEs and PRI frequen-
cies, SCEs and MI frequencies and PRI and MI fre-
quencies were also calculated using Pearson’s product
moment correlation coefficient.
ReSulTS
Table I illustrates the effect of agomelatine on SCE
frequency. Cultured T lymphocyte SCE frequency is
presented as dose-dependent increase after the effect
of agomelatine solutions: B=5μg/ml, C=10μg/ml,
D=15μg/ml and E=20μg/ml (final concentrations per
culture). This increase is statistically significant
(P<0,001) and indeed the concentration of 10μg/ml
duplicates the SCE rate in cultured lymphocytes of all
blood donors, though a small decrease (not statistically
significant) in SCE rate is observed at concentration
of 2.5μg/ml in all lymphocyte cultures.
Table i. Effect of Agomelatine on SCE frequency in human
lymphocyte cultures from four healthy donors 
Dosage SCEs /cell
(μg/ml) 1st donor 2nd donor 3rd donor 4th donor
Control
(H2O) 5,28 5,12 6,01 7,1
2,5 5,1 4,8 5,9 6,9
5 7,9* 7,43* 9,07* 9,87*
10 10,16* 9,93* 11,31* 12,22*
15 12,71* 11,49* 13,68* 13,97*
20 15,1* 14,82* 14,92* 15,6*
*Statistically significant (p<0,001) increase over the corresponding
control (t-test) 
SCEs have been correlated with corresponding PRI values (r= -0.971,
p<0.001). 
The Pearson product moment correlation coefficient r was applied for
calculating the correlation between SCEs and PRIs. A criterion for
testing whether r differs significantly from zero was used whose sampling
distribution is Students test with n-2 degrees of freedom.
Table II illustrates the effect of agomelatine on
PRI. Agomelatine solutions of 2.5μg/ml, 5μg/ml,10μg/ml
and 15μg/ml induce not statistically significant decrease,
though the solution of 20μg/ml causes a remarkable
decrease on PRI values of cultured T lymphocytes, s-
tatistically significant (P<0,001). 
Table III presents the effect of agomelatine on MI
values. Agomelatine solutions cause a decrease of MI
on lymphocytes. Specifically the solutions of 5μg/ml,
10μg/ml, 15μg/ml and 20μg/ml induce statistically sig-
nificant decrease (P<0,001). Furthermore, a correlation
was observed (P<0.001) between:
1. the magnitude of the SCE induction and the MI al-
terations 
2. the MI alterations and PRI alterations and
3. the magnitude of the SCE induction and the PRI
alterations
Table ii. Effect of Agomelatine on PRI frequency in human
lymphocyte cultures from four healthy donors 
Dosage SCEs /cell
(μg/ml) 1st donor 2nd donor 3rd donor 4th donor
Control
(H2O) 2,41 2,45 2,4 2,52
2,5 2,34 2,37 2,33 2,43
5 2,25 2,29 2,26 2,36
10 2,29 2,33 2,31 2,40
15 2,33 2,36 2,32 2,42
20 2,14** 2,17** 2,21** 2,23**
**Statistically significant (p<0.001) decrease over the corre-
sponding control (χ² test)
Table iii. Effect of Agomelatine on MI frequency in human
lymphocyte cultures from four healthy donors 
Dosage SCEs /cell
(μg/ml) 1st donor 2nd donor 3rd donor 4th donor
Control
(H2O) 38 40 39 43
2,5 36 37 36 40
5 30*** 29*** 29*** 35***
10 31*** 32*** 30*** 37***
15 34 33*** 33*** 38
20 25*** 26*** 26*** 30***
***Statistically significant (p<0.001) decrease over the corre-
sponding control (χ² test)
diSCuSSiOn 
Depression is one of the most significant causes of dis-
ability worldwide. Despite the variety of effective treat-
ment strategies available, almost one third of the pa-
tients fail to respond to antidepressant therapies1.
There is a need for more effective and better tolerated
antidepressants to combat the depression characteristics
(behavioral, cognitive and emotional). Understanding
the pathophysiology of depression and finding new
treatment strategies is of great importance. 
Agomelatine is a novel drug recently added to the
list of the antidepressants available. The specificity of
its mechanism of action, as a potent agonist of melatonin
MT1 and MT2 receptors as well as an antagonist of
serotonin 5-HT(2C) receptors, may provide a useful,
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alternative pharmacological strategy to existing antide-
pressant drugs2,3,4.
The present research investigates the cytogenetic
behavior of agomelatine on healthy human T lympho-
cyte cultures estimating the most reliable indices of cy-
togenetic damage: SCEs, PRI and MI. In addition, this
method also has the advantage of testing the indices
mentioned above in human CD4 and CD8 T lympho-
cytes. Recent data from laboratory animal studies show
that T lymphocytes may have a protective role against
depression by producing IL-4. This production leads
to the increase of Brain Derivative Neurotrophic Factor
(BDNF) levels by astrocytes and to the conversion of
meningeal macrophages to M2 phenotype. Both CD4
and CD8 T lymphocytes also express melatonin recep-
tors16,17,18,19.
The SCEs significant induction (Figure 2) of cul-
tured lymphocytes from all four blood donors after
treatment with therapeutic doses of agomelatine may
indicate an insufficiency in DNA damage repairing.
High SCEs values could also demonstrate a considerable
DNA damage which could not be repaired before T
cells reach S phase in vitro20,21. This means that agome-
latine induces DNA damage at therapeutic doses in
vitro or that agomelatine affects cell repair system,
which is notable to repair the damage caused22. This
should be further investigated. The possible alterations
in immune response of T lymphocytes and cytokine se-
cretion caused by DNA damage should also be inves-
tigated. In Table I it is also shown that subtherapeutic
dose of agomelatine (2.5μg/ml) causes a reduction of
SCE frequency. Although the decrease is not statistically
significant, it is an interesting finding in cultured lym-
phocytes of all donors, considering the protective role
of T lymphocytes in depression16. Agomelatine in s-
maller doses may have a protective role to DNA
molecule possibly due to the reinforcement of repair
mechanisms.
As recently the interest of scientists about the role
of inflammation in depression is increased, cultured
lymphocyte cytogenetic response after agomelatine
treatment provides us with further information for the
mechanism of action of agomelatine in the inflammatory
pathway of depression.
According to Table II therapeutic doses of agome-
latine (Figure 3) do not affect the proliferation rate
(PRI) and only the higher concentration of 20μg/ml
induces a remarkable decrease on PRI values of cul-
tured T lymphocytes, statistically significant (P<0,001). 
On the contrary, the statistically significant induction
of lymphocyte MI values (Figure 4) after the effect of
therapeutic doses shows that agomelatine has a cytostatic
behavior in vitro, which needs further investigation.
This preliminary study shows that agomelatine has
a very interesting cytogenetic behavior and it also pro-
vides information about the unknown inflammatory
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Figure 2. Effect of Agomelatine on SCE frequency in human lymphocyte cultures from four healthy donors.
path of depression. Our next step is the investigation
of cytogenetic behavior of agomelatine at a larger
amount of donors, at different cell lines (B lymphocytes
and macrophages), in vivo experiments and DNA repair
enzymes (DNA ligase, topoisomerases) measurements.
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1. De Berardis D, Marini S, Fornaro M, Srinivasan V, Ia-
sevoli F, Tomasetti C, Valchera A, Perna G, Quera-Salva
MA, Martinotti G, di Giannantonio M. The melatonergic
system in mood and anxiety disorders and the role of
agomelatine: implications for clinical practice. Int J Mol
Sci. 2013;14(6):12458-83.
2. Milanese M, Tardito D, Musazzi L, Treccani G, Mallei
A, Bonifacino T, Gabriel C, Mocaer E, Racagni G, Popoli
M, Bonanno G. Chronictreatment with agomelatine or
venlafaxine reduces depolarization-evoked glutamate
release from hippocampal synaptosomes. BMC Neurosci.
2013;14:75. 
3. De Berardis D, Fornaro M, Serroni N, Campanella D,
Rapini G, Olivieri L, Srinivasan V, Iasevoli F, Tomasetti
C, De Bartolomeis A, Valchera A, Perna G, Mazza M,
Di Nicola M, Martinotti G, Di Giannantonio M. Agome-
latine beyond borders: current evidences of its efficacy
in disorders other than major depression. Int J Mol Sci.
2015;16(1):1111-30. 
4. Taylor D, Sparshatt A, Varma S, Olofinjana O. Antide-
pressant efficacy of agomelatine: meta-analysis of pub-
lished and unpublished studies. BMJ. 2014;348:g1888 
5. Poeggeler B, Saarela S, Reiter RJ, Tan DX, Chen LD,
Manchester LC, Barlow-Walden LR (November 1994).
6 Aristotle University Medical Journal, Vol. 43, Issue 1, February 2016
ReFeRenCeS
Επίδραση της Αγομελατίνης στο Γενετικό Υλικό του Ανθρώπου:
In vitro μελέτη
Γεώργιος Δεμιρτζόγλου1,2, Σοφία-Ιφιγένεια Χρύσογλου1, Δήμος Δημέλης3, 
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Εισαγωγή: Η αγομελατίνη αποτελεί ένα εγκεκριμένο φάρμακο για τη θεραπεία της μείζονος καταθλιπτικής διαταραχής.
Παρουσιάζει δράση μελατονινεργικού αγωνιστή και ανταγωνιστή των 5-HT2C υποδοχέων της σεροτονίνης. Σκοπός της
παρούσας έρευνας είναι η μελέτη της επίδρασης της αγομελατίνης στο ανθρώπινο DNA in vitro με τον υπολογισμό
ευαίσθητων κυτταρογενετικών δεικτών.
Υλικό και Μέθοδος: Oι χρωματιδιακές ανταλλαγές (Sister Chromatid Exchanges, SCEs) θεωρούνται ένας από τους πιο
ευαίσθητους δείκτες γονοτοξικότητας. O δείκτης ρυθμού πολλαπλασιασμού (Proliferation Rate Index, PRI) είναι ένας
από τους πιο αξιόπιστους δείκτες κυτταροστατικότητας, ενώ ο μιτωτικός δείκτης (Mitotic Index, MI) δείχνει με ακρίβεια
την ικανότητα του κυττάρου για πολλαπλασιασμό. 
Αρχικά παρασκευάστηκαν διαλύματα αγομελατίνης πέντε διαφορετικών συγκεντρώσεων (A=2.5μg/ml, B=5μg/ml,
C=10μg/ml, D=15μg/ml και E=20μg/ml). Oι συγκεντρώσεις B και C είναι οι πιο συχνά χρησιμοποιούμενες στην κλινική
πράξη. Τα διαλύματα προστέθηκαν σε καλλιέργειες λεμφοκυττάρων από περιφερικό αίμα τεσσάρων νεαρών υγειών αι-
μοδοτών. Μετά από 72 ώρες επώασης, με την κατάλληλη τεχνική τα καλλιεργημένα λεμφοκύτταρα επιστρώθηκαν σε αν-
τικειμενοφόρους πλάκες, χρωματίστηκαν με την μέθοδο Fluorescence plus Giemsa και οι προαναφερθέντες δείκτες υπο-
λογίστηκαν με οπτικό μικροσκόπιο.
Αποτελέσματα: Η ανάλυση των αποτελεσμάτων αποκάλυψε στατιστικά σημαντική αύξηση των χρωματιδιακών ανταλλαγών
και μείωση τόσο του δείκτη ρυθμού πολλαπλασιασμού όσο και του μιτωτικού δείκτη . Επιπρόσθετα, προέκυψε συσχέτιση
μεταξύ α) της αύξησης των SCEs και των μεταβολών του ΜΙ και του PRI και β) των μεταβολών ΜΙ-PRI.
Συμπεράσματα: Η αγομελατίνη σε θεραπευτικές δόσεις προκάλεσε δοσοεξαρτώμενες μεταβολές στους υπό μελέτη κυτ-
ταρογενετικούς δείκτες. Το παραπάνω ενδέχεται να καταδεικνύει στοιχεία για το μηχανισμό δράσης του φαρμάκου. Λαμ-
βάνοντας υπόψη την αυξανόμενη χρήση της αγομελατίνης επιβάλλεται περεταίρω μελέτη της κυτταρογενετικής της δράσης
σε περισσότερους αιμοδότες καθώς και σε άλλες κυτταρικές σειρές.
Λέξεις-Κλειδιά: Αγομελατίνη, Γονοτοξικότητα, Χρωματιδιακές ανταλλαγές, Δείκτης ρυθμού πολλαπλασιασμού, Μιτωτικός
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